MDT

86.48

+0.17%↑

115.41

+0.39%↑

VEEV

173.76

-0.87%↓

HQY

84.36

+0.97%↑

PHR.US

8.25

-1.67%↓

MDT

86.48

+0.17%↑

115.41

+0.39%↑

VEEV

173.76

-0.87%↓

HQY

84.36

+0.97%↑

PHR.US

8.25

-1.67%↓

MDT

86.48

+0.17%↑

115.41

+0.39%↑

VEEV

173.76

-0.87%↓

HQY

84.36

+0.97%↑

PHR.US

8.25

-1.67%↓

MDT

86.48

+0.17%↑

115.41

+0.39%↑

VEEV

173.76

-0.87%↓

HQY

84.36

+0.97%↑

PHR.US

8.25

-1.67%↓

MDT

86.48

+0.17%↑

115.41

+0.39%↑

VEEV

173.76

-0.87%↓

HQY

84.36

+0.97%↑

PHR.US

8.25

-1.67%↓

Inicio・Lista de Acciones・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Abierto

SectorSanidad

24.51 -0.89

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

24.23

Máximo

24.99

Métricas clave
By Trading Economics
Ingresos	-85K 53M
Ventas	4.2M 153M
P/B Media del Sector	14.155 56.063
BPA	0.68
Margen de beneficios	34.53
Empleados	182
EBITDA	612K 81M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+39.34% upside

Dividendos
By Dow Jones
Próximas Ganancias	6 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-41M 2.9B
Apertura anterior	25.4
Cierre anterior	24.51

Noticias sobre sentimiento de mercado

By Acuity

34%

66%

107 / 349 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

N/A / 24.28 Soporte y Resistencia

Catalyst Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

1 abr 2026, 22:56 UTC

Noticias de Eventos Importantes

Australian PM Set To Announce Interest-Free Loans For Businesses, Farmers

1 abr 2026, 20:50 UTC

Adquisiciones, fusiones, absorciones

Gilead Extends Deadline on Tender Offer to Acquire Arcellx

1 abr 2026, 23:55 UTC

Charlas de Mercado

Gold Rises on Hopes for Early End to U.S.-Iran Conflict -- Market Talk

1 abr 2026, 23:43 UTC

Charlas de Mercado

Nikkei May Rise on Continued Hopes for U.S. Ending Iran War -- Market Talk

1 abr 2026, 23:23 UTC

Noticias de Eventos Importantes

South Korea Consumer Inflation Accelerates on Mideast Energy Shock -- Update

1 abr 2026, 23:07 UTC

Ganancias

Shake Shack Leans on Loyalty Program and Tech to Drive Growth -- Barrons.com

1 abr 2026, 23:02 UTC

Noticias de Eventos Importantes

South Korea Consumer Inflation Accelerates on Mideast Energy Shock

1 abr 2026, 23:00 UTC

Noticias de Eventos Importantes

S Korea Mar CPI +0.3% on Month; +0.6% Forecast

1 abr 2026, 23:00 UTC

Noticias de Eventos Importantes

S Korea Mar Core CPI +2.2% on Year, +0.1% on Month

1 abr 2026, 23:00 UTC

Noticias de Eventos Importantes

S Korea Mar CPI +2.2% on Year; +2.4% Forecast

1 abr 2026, 22:39 UTC

Ganancias

Nike Can't Fix Its China Problem and That's Tanking Its Stock -- Update

1 abr 2026, 22:08 UTC

Charlas de Mercado

KKR BDC Joins Others in Capping Withdrawals at 5% -- Market Talk

1 abr 2026, 22:00 UTC

Noticias de Eventos Importantes

Mideast War Rekindles Asia Inflation Risk, Says DBS Chief Economist -- Interview

1 abr 2026, 22:00 UTC

Noticias de Eventos Importantes

DBS Chief Economist: Rate Hikes Seem Likely in Japan, Singapore, Australia

1 abr 2026, 22:00 UTC

Noticias de Eventos Importantes

DBS Chief Economist: BOK Could Also Take Proactive Approach Like RBA

1 abr 2026, 22:00 UTC

Noticias de Eventos Importantes

DBS Chief Economist: India Vulnerable to War Imapct on Both Trade, Energy

1 abr 2026, 22:00 UTC

Noticias de Eventos Importantes

DBS Chief Economist: China, Malaysia Looks Relatively Well-Insulated From War Fallout

1 abr 2026, 22:00 UTC

Noticias de Eventos Importantes

DBS Chief Economist: Mideast Crisis Won't Hurt Asia Growth Much, Inflation a Bigger Issue

1 abr 2026, 22:00 UTC

Noticias de Eventos Importantes

Inflationary Impact of Mideast Conflict Seems Inevitable, DBS Group Chief Economist Says

1 abr 2026, 21:56 UTC

Adquisiciones, fusiones, absorciones

BHP Completes $4.3 Billion Silver Streaming Agreement With Wheaton Precious Metals

1 abr 2026, 21:31 UTC

Noticias de Eventos Importantes

End to Iran War Could Trigger Relief Rally in These 2 Assets -- Barrons.com

1 abr 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

1 abr 2026, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

1 abr 2026, 20:38 UTC

Ganancias

Why Nike Stock Is in 'Penalty Box' After Earnings Beat -- Barrons.com

1 abr 2026, 20:31 UTC

Adquisiciones, fusiones, absorciones

Arsenal Capital Partners Completes Sale of ATP Adhesive Systems to Henkel

1 abr 2026, 20:16 UTC

Adquisiciones, fusiones, absorciones

Gilead: Tender Offer Extended to Expire at 5 p.m. EDT on April 24 >GILD

1 abr 2026, 20:16 UTC

Adquisiciones, fusiones, absorciones

Gilead: Offer Remains at a Purchase Price of $115.00 per Shr >GILD

1 abr 2026, 20:13 UTC

Adquisiciones, fusiones, absorciones

Gilead Extends Tender Offer To Acquire Arcellx >GILD

1 abr 2026, 20:07 UTC

Charlas de Mercado

Mexican Manufacturing Indexes Pick Up in March -- Market Talk

1 abr 2026, 20:07 UTC

Adquisiciones, fusiones, absorciones

Why 2026 Is Biotech's Comeback Year -- Barrons.com

Comparación entre iguales

Cambio de precio

Catalyst Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

39.34% repunte

Estimación a 12 Meses

Media 34.5 USD 39.34%

Máximo 35 USD

Mínimo 33 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

N/A / 24.28Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Sentimiento

By Acuity

107 / 349 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.